Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy.

TMB-high advanced gastric cancer patients accounted for around one-sixth and had a poorer prognosis than TMB-low patients when treated with first-line chemotherapy. The potential mechanism might be the downregulated metabolic activity in TMB-high patients.